Drug reference

Dacarbazine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 968

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Metastatic melanoma | Soft-tissue sarcomas (combination therapy) | Hodgkin’s disease (combination therapy) ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Adult: (consult local protocol)

PDF page 968

Cautions

Caution in handling—irritant to tissues

PDF page 968

Prescribing And Dispensing Information

Dacarbazine is a component of a commonly used combination for Hodgkin’s disease (ABVD—doxorubicin [previously Adriamycin ®], bleomycin, vinblastine, and dacarbazine).

PDF page 968

Safety

Interactions

→Appendix 1: alkylating agents

PDF page 968

Side Effects

▶Common or very common Anaemia. appetite decreased. leucopenia. nausea. thrombocytopenia. vomiting ▶Uncommon Alopecia. infection. inﬂuenza like illness. photosensitivity reaction. skin reactions ▶Rare or very rare Agranulocytosis. confusion. diarrhoea. ﬂushing. headache. hepatic disorders. lethargy. pancytopenia. paraesthesia. renal impairment. seizure. visual impairment

PDF page 968

Conception And Contraception

Ensure effective contraception during and for at least 6 months after treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 968

Pregnancy

Avoid (carcinogenic and teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 968

Breast Feeding

Discontinue breast-feeding.

PDF page 968

Hepatic Impairment

Avoid in severe impairment. Dose adjustments Dose reduction may be required in combined renal and hepatic impairment.

PDF page 968

Renal Impairment

Avoid in severe impairment. Dose adjustments Dose reduction may be required in combined renal and hepatic impairment.

PDF page 968

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ▶Dacarbazine (Non-proprietary) Dacarbazine (as Dacarbazine citrate) 500 mg Dacarbazine 500mg powder for solution for infusion vials | 1 vial P £37.50 Dacarbazine (as Dacarbazine citrate) 1 gram Dacarbazine 1g powder for solution for infusion vials | 1 vial P £70.00 Powder for solution for injection ▶Dacarbazine (Non-proprietary) Dacarbazine (as Dacarbazine citrate) 100 mg Dacarbazine 100mg powder for solution for injection vials | 10 vial P £90.00 Dacarbazine (as Dacarbazine citrate) 200 mg Dacarbazine 200mg powder for solution for injection vials | 10 vial P £160.00

PDF page 968

Dose text by age group

Adult

(consult local protocol)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 968

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Dacarbazine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 968

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Metastatic melanoma | Soft-tissue sarcomas (combination therapy) | Hodgkin’s disease (combination therapy) ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Adult: (consult local protocol)

PDF page 968

Cautions

Caution in handling—irritant to tissues

PDF page 968

Prescribing And Dispensing Information

Dacarbazine is a component of a commonly used combination for Hodgkin’s disease (ABVD—doxorubicin [previously Adriamycin ®], bleomycin, vinblastine, and dacarbazine).

PDF page 968

Safety

Interactions

→Appendix 1: alkylating agents

PDF page 968

Side Effects

PDF page 968

Conception And Contraception

Ensure effective contraception during and for at least 6 months after treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 968

Pregnancy

Avoid (carcinogenic and teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 968

Breast Feeding

Discontinue breast-feeding.

PDF page 968

Hepatic Impairment

Avoid in severe impairment. Dose adjustments Dose reduction may be required in combined renal and hepatic impairment.

PDF page 968

Renal Impairment

Avoid in severe impairment. Dose adjustments Dose reduction may be required in combined renal and hepatic impairment.

PDF page 968

Dose and formulations

Medicinal Forms

PDF page 968

Dose text by age group

Adult

(consult local protocol)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 968

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.